Botox in ENT
Reading File
Finding Sources
Finding Sources
Searching PubMed
botulinum toxin ENT head neck
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I now have excellent content from multiple authoritative ENT textbooks. Let me compile the comprehensive answer.
Botulinum Toxin (Botox) in ENT
Mechanism of Action
Botulinum toxin (BTX) is produced by Clostridium botulinum. Eight antigenically distinct serotypes (A-H) exist; Type A (BoNT-A) has the widest pharmaceutical use. It works by blocking presynaptic release of acetylcholine via inactivation of SNAP-25 (25-kDa synaptosome-associated protein), which is essential for fusion and release of acetylcholine-containing vesicles at the nerve terminal. This results in chemical denervation of the target muscle or gland.
- Onset: 2-3 days after injection
- Duration: 3-9 months (varies by product and site)
Commercial preparations (Botox/onabotulinumtoxinA, Dysport/abobotulinumtoxinA, Xeomin/incobotulinumtoxinA) differ in molecular structure and manufacturing, so dosing is not interchangeable between products.
ENT Applications
1. Spasmodic Dysphonia (Laryngeal Dystonia)
The most established ENT indication. Spasmodic dysphonia is a focal dystonia of the larynx - frequently misdiagnosed but readily amenable to BTX.
| Type | Muscle Injected | Technique |
|---|---|---|
| Adductor (strained, effortful voice) | Thyroarytenoid (TA) ± lateral cricoarytenoid (LCA) | Percutaneous (transcricothyroid/transtracheal) or endoscopic, EMG-guided |
| Abductor (breathy, whispery breaks) | Posterior cricoarytenoid (PCA) | More technically demanding; posterior approach |
- Effect lasts 3-6 months; repeat injections required indefinitely
- BTX is the first-line treatment for spasmodic dysphonia, preferred over surgery
- Also used for contact granulomas - bilateral adductor injection at ~10x the standard SD dose reduces the hyperadduction responsible for granuloma formation
- Harrison's 22e confirms: "Botulinum toxin is the preferred treatment for patients with focal and segmental dystonia... particularly in spasmodic dysphonia" - Harrison's Principles of Internal Medicine, 22e
2. Sialorrhea (Drooling)
A major ENT application, particularly in pediatric neurological patients (cerebral palsy, neurodegenerative disease).
Mechanism: Chemical parasympathetic denervation of salivary glands reduces secretion.
Technique options:
- Injection guided by anatomic landmarks + manual palpation
- Ultrasound guidance (preferred for accuracy, especially in children)
- EMG guidance
Glands targeted: Parotid and/or submandibular glands (bilateral)
Key points from Cummings Otolaryngology:
- A review of 1,200 injections showed no deaths and no major morbidities
- 10% of patients are non-responders regardless of dose
- Duration of effect: 3-9 months, requiring periodic re-injection
- Important caveat: BTX treatment decreases salivary pH, increasing dental caries risk - patients (especially children) need enhanced dental surveillance
- Chronic use reduces salivary gland size ultrasonographically (no significant histological change)
- FDA warnings: serious adverse effects including dysphagia, aspiration pneumonia, and distal muscle weakness can occur from toxin diffusion or inadvertent injection into neck muscles
Stepwise management: rehabilitation (oral motor therapy) → anticholinergics → BTX injection → salivary gland surgery (excision or duct rerouting)
3. Facial Nerve Synkinesis
Following facial nerve injury/Bell's palsy, aberrant regeneration causes synkinesis (involuntary movement with voluntary movement). BTX is used in nearly 50% of patients in dedicated facial function clinics (Scott-Brown's).
Specific synkinesis patterns treated:
| Pattern | BTX Target |
|---|---|
| Ocular synkinesis (involuntary eye closure) | Orbicularis oculi - caution: risk of ptosis and diplopia |
| Epiphora / Bogorad syndrome (crocodile tears) | Lacrimal gland |
| Mentalis synkinesis (chin dimpling) | Mentalis muscle |
| Platysmal synkinesis | Platysmal bands |
| Lower lip asymmetry | Contralateral depressor labii inferioris |
- Also used on the non-paralyzed side to improve symmetry
- Used for facial contractures post-Bell's palsy
- Preparation (Scott-Brown's protocol): 500 units Dysport in 5 mL saline (10 units/0.1 mL); 45-degree angle with insulin syringe; initial dose ~10 units per synkinetic muscle; adjusted at 6 months
4. Non-Allergic Rhinitis (NAR) - Rhinorrhea
- BTX injected intranasally into the head of the inferior and middle turbinates
- Mechanism: anticholinergic effect on secretory activity of nasal mucosa
- Reduces rhinorrhea but does not address nasal obstruction, sneezing, or other non-rhinorrhea symptoms
- Effect is temporary (~12 weeks)
- Safe with no significant side effects at standard dosing
5. Cricopharyngeal Dysfunction / Dysphagia
- BTX injected into the cricopharyngeal muscle (upper esophageal sphincter)
- Routes: percutaneous or endoscopic injection
- Effective in cricopharyngeal spasm following head/neck surgery, neurogenic dysphagia (post-stroke), and oculopharyngeal muscular dystrophy (OPMD)
- Single injection post-stroke may improve swallowing for up to 12 months
- Success is variable; acts as a bridge before considering cricopharyngeal myotomy
6. Frey Syndrome (Auriculotemporal Nerve Syndrome)
- Gustatory sweating over the preauricular area after parotidectomy (aberrant reinnervation of sweat glands by parasympathetic parotid fibers)
- BTX injected intradermally into affected area
- Andrews' Dermatology: "Frey syndrome remits for 1-10 years in almost every patient treated"
- Type B is also effective but has a more limited duration of response
Summary Table
| ENT Indication | Muscle / Gland | Route | Duration |
|---|---|---|---|
| Spasmodic dysphonia (adductor) | Thyroarytenoid | Percutaneous/endoscopic EMG-guided | 3-6 months |
| Spasmodic dysphonia (abductor) | Posterior cricoarytenoid | Percutaneous posterior | 3-6 months |
| Contact granuloma | Bilateral TA/LCA (high dose) | Percutaneous | Variable |
| Sialorrhea | Parotid, submandibular | US/palpation-guided | 3-9 months |
| Facial synkinesis | Orbicularis, platysma, etc. | Intradermal/intramuscular | 3-6 months |
| Rhinorrhea (NAR) | Inferior/middle turbinate mucosa | Intranasal | ~12 weeks |
| Cricopharyngeal dysfunction | Cricopharyngeus | Endoscopic or percutaneous | Up to 12 months |
| Frey syndrome | Preauricular skin | Intradermal | 1-10 years |
Contraindications and Precautions
- Neuromuscular junction disorders (myasthenia gravis, Lambert-Eaton) - relative contraindication
- Pregnancy and breastfeeding
- Local infection at injection site
- Concurrent aminoglycosides (potentiate effect)
- Non-interchangeability between preparations (dose conversion not linear)
- Risk of diffusion with higher doses: dysphagia, aspiration, ptosis, diplopia
Sources: Cummings Otolaryngology Head and Neck Surgery, Scott-Brown's Otorhinolaryngology Head & Neck Surgery, K.J. Lee's Essential Otolaryngology, Harrison's Principles of Internal Medicine 22e
Occult primary N2 lesion differential diagnosis and management
Reading File
Finding Sources
Finding Sources
Searching PubMed
"occult primary" AND "cervical lymph node" AND head neck
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
This is a shared conversation. Sign in to Orris to start your own chat.